What is Halozyme Therapeutics's free cash flow?

Halozyme Therapeutics (HALO) reported free cash flow of $176.34M in Q1 2026.

How has Halozyme Therapeutics's free cash flow changed year-over-year?

Halozyme Therapeutics's free cash flow increased by 15.0% year-over-year, from $153.27M to $176.34M.

What is the long-term trend for Halozyme Therapeutics's free cash flow?

Over 4 years (2021 to 2025), Halozyme Therapeutics's free cash flow has grown at a 21.3% compound annual growth rate (CAGR), from $297.98M to $644.59M.

Halozyme Therapeutics HALO Free cash flow

Free cash flow at other companies

AbbVieABBV

$3.56B+155%

West Pharmaceutical ServicesWST

——

BridgeBio PharmaBBIO

——

Arrowhead ResearchARWR

——

AptarGroupATR

——

AlkermesALKS

——

Other financials

Income statement

See full

Revenue$376.7M+42.2%

Gross profit$297.5M+37.4%

Operating income$184.5M+30.4%

Net income$150.0M+27.1%

EPS (diluted)$1.22+31.2%

Balance sheet

See full

Cash & equivalents$312.0M+76.9%

Total debt$2.2B+41.7%

Total equity$219.6M-54.5%

Total assets$2.7B+21.7%

Cash flow

See full

Operating cash flow$180.1M+16.8%

CapEx$3.7M+294%

Valuation

See full

Market cap$8.13B-2.9%

Enterprise value$10B+3.0%

P/E13.4×-3.8×

P/S5.4×-2.3×

Profitability

See full

Gross margin82.8%-0.7pp

Operating margin59.3%+9.0pp

Net margin47.9%+6.5pp

FCF margin44.3%-1.5pp

Returns & leverage

See full

Return on equity124.5%+12.7pp

Debt / equity9.9×+6.7×

Current ratio2.8×-5.6×

Where this comes from

Calculated from Halozyme Therapeutics’s reported figures.

$180.1Mnet cash from operating−$3.7Mcapital expenditures=$176.34M

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Halozyme Therapeutics's free cash flow?: Halozyme Therapeutics (HALO) reported free cash flow of $176.34M in Q1 2026.
How has Halozyme Therapeutics's free cash flow changed year-over-year?: Halozyme Therapeutics's free cash flow increased by 15.0% year-over-year, from $153.27M to $176.34M.
What is the long-term trend for Halozyme Therapeutics's free cash flow?: Over 4 years (2021 to 2025), Halozyme Therapeutics's free cash flow has grown at a 21.3% compound annual growth rate (CAGR), from $297.98M to $644.59M.